MedPath

Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

Phase 4
Terminated
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo (placebo comparator)
Drug: Nux vomica (active comparator)
Registration Number
NCT00861237
Lead Sponsor
Medical University of Vienna
Brief Summary

After heart surgery, about 30% of patients suffer from atrial fibrillation. Patients are randomized into two groups receiving either potentized Strychnos Nux vomica or placebo under double blind conditions. Postoperatively, ECGs are done to monitor cardiac rhythm.

Detailed Description

Preoperatively, patients receive potentized Nux vomica or placebo sublingually. Then, patients are observed regarding atrial fibrillation postsurgical. The difference between the group of patients with and without nux vomica is recorded.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Patients before elective Heart valve - or aortocoronary by pass surgery with heart-lung-machine.
Exclusion Criteria
  • Pregnant patients
  • Patients with preoperative atrial fibrillation and/or hyperthyreosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo globules groupPlacebo (placebo comparator)Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
Nux vomica groupNux vomica (active comparator)Patients receive Nux vomica globules made out of sugar sublingually before surgery.
Primary Outcome Measures
NameTimeMethod
Frequency of atrial fibrillation after heart surgery with heart lung machine24 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Dept Surgery, Med Univ Vienna

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath